Stockscreener 앱 받기
68.99
7.78%
4.98
시간 외 거래:
70.20
1.21
+1.75%
전일 마감가:
$64.01
열려 있는:
$67.75
하루 거래량:
4.20M
Relative Volume:
4.83
시가총액:
$5.44B
수익:
$688.00K
순이익/손실:
$-135.82M
주가수익비율:
-33.20
EPS:
-2.078
순현금흐름:
$-169.41M
1주 성능:
+32.72%
1개월 성능:
+72.95%
6개월 성능:
+210.91%
1년 성능:
+442.80%
1일 변동 폭
$64.60
$69.45
1주일 범위
$50.85
$75.00
52주 변동 폭
$12.04
$75.00
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
68.99 | 5.04B | 688.00K | -135.82M | -169.41M | -2.078 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal - MSN
SYRE Secures $403M Common Stock Offering - GuruFocus
Spyre Therapeutics Announces $403M Public Offering - National Today
SYRE Maintained by Deutsche Bank -- Price Target Raised to $88 - GuruFocus
Spyre Therapeutics prices $403M public stock offering at $62 - Investing.com
Spyre Therapeutics announces pricing of upsized $403 million public offering of common stock - marketscreener.com
Spyre Therapeutics Announces $403 Million Public Offering of Common Stock - Quiver Quantitative
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
SYRE Maintained by Wedbush -- Price Target Raised to $80.00 - GuruFocus
SYRE Maintained by Baird -- Price Target Raised to $90.00 - GuruFocus
Spyre Therapeutics launches $300 million stock offering By Investing.com - Investing.com Australia
SYRE Initiated Coverage by Raymond James -- Strong Buy Rating As - GuruFocus
Mizuho Boosts Price Target on Spyre Therapeutics to $84 From $53, Keeps Outperform Rating - Moomoo
SYRE Maintained by Wells Fargo -- Price Target Raised to $90 - GuruFocus
SYRE Initiated Coverage by Raymond James -- Strong Buy Rating Assigned - GuruFocus
Spyre Therapeutics: Strong SPY001 Data Sets Up A Catalyst-Rich 2026 (NASDAQ:SYRE) - Seeking Alpha
Deutsche Bank Adjusts Spyre Therapeutics PT to $88 From $55, Maintains Buy Rating - marketscreener.com
Spyre Sees Monotherapy Potential For UC Drug After Phase II Data - Citeline News & Insights
Positive Phase 2 Results Boost Spyre Therapeutics (SYRE) - GuruFocus
Spyre Therapeutics, Inc. (SYRE) Files 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative ColitisSlideshow (NASDAQ:SYRE) 2026-04-14 - Seeking Alpha
SYRE Maintains by Jefferies -- Price Target Raised to $85.00 - GuruFocus
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics (SYRE) Launches $300M Public Offering to Fund Treatment Development - GuruFocus
Spyre Therapeutics (SYRE) Boosts Confidence in SPY001 Data - GuruFocus
Raymond James initiates Spyre stock with strong buy rating - Investing.com UK
Spyre (SYRE) Announces Stellar UC Treatment Trial, Hits 4-Year High - Insider Monkey
SYRE Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
Spyre Therapeutics (SYRE) Initiates $300 Million Stock Offering - GuruFocus
Spyre Therapeutics (SYRE) Reveals Promising Results in Ulcerativ - GuruFocus
Spyre Therapeutics stock falls on $300M stock offering - Investing.com
Spyre Therapeutics stock falls on $300M stock offering By Investing.com - Investing.com Canada
Spyre Therapeutics (NASDAQ: SYRE) seeks $300M via common stock offering; SPY001 shows strong Phase 2 topline - Stock Titan
Spyre Therapeutics launches $300 million stock offering - Investing.com
Spyre’s SPY-001 induces better outcomes in ulcerative colitis - BioWorld News
Raymond James initiates Spyre stock with strong buy rating By Investing.com - Investing.com South Africa
Spyre Therapeutics' Trial Data Boosts Stock by 23% - Intellectia AI
Spyre Therapeutics announces proposed public offering of its common stock - marketscreener.com
Spyre Therapeutics Inc suspends and terminates ATM prospectus for at-the-market offering effective April 13, 2026SEC filing - marketscreener.com
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - The Manila Times
Spyre Therapeutics IncSuspends And Terminates ATM Prospectus For At-The-Market Offering Effective April 13, 2026SEC Filing - TradingView — Track All Markets
Small U.S. Stocks Close Up; Spyre Therapeutics Leads Increases - Moomoo
SYRE Stock Jumps As Stifel Hikes Price Target To $92 - timothysykes.com
Spyre moves to raise $300M, with room to expand the sale to $345M - Stock Titan
Spyre Therapeutics (NASDAQ: SYRE) ends ATM prospectus, reports $741M cash - Stock Titan
SYRE Maintained by BTIG -- Price Target Raised to $98.00 - GuruFocus
Spyre Therapeutics Reports Positive Phase 2 SKYLINE Results - TipRanks
Jefferies raises Spyre stock price target to $85 on trial data - Investing.com Canada
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):